first thought i i read fda release approval vyvanse binge eating disorder i thought rotation i eating disorder service university minnesota top experts anorexia nervosa bulimia days residents admitted patients also rotated outpatient clinic saw new cases eating disorders developed treatment plans supervision attendings talked lot binge eating since binge eating critical aspect bulimic behavior ever consume amount food large enough might embarrassing someone else found getting details specific behavior one standard interview questions clear binge eating bulimia volume rate task i would hear large amounts diet soda popcorn consumed order complete cycle intervening decades real changes addition bulimia nervosa composite bulimic anorexic behaviors advent binge eating disorder dsm addition binge definition much different one i used eating amount food definitely larger people would ingest period similar circumstances loss control behavioral specifiers rapidity physical sensations appetite psychological reactions binge eating marked distress needs occur part another eating disorder time specifier needs occur least week months summary fda release indication states binge eating cause serious health problems difficulties work home social life said mitchell mathis director division psychiatry products fda center drug evaluation research approval vyvanse provides physicians patients effective option help curb episodes binge eating dsm point prevalence estimate women peak late adolescence early adulthood section dsm suggests course variable however longer term follow symptoms many individuals appear diminish without treatment although treatment clearly impacts outcome periods remission longer year associated better long term outcome dsm p far i tell evidence supporting fast tracked application vyvanse typical week clinical trial looked remission reduction binge eating rates multicenter study individuals mg doses effective publication research coincides fairly closely fda release searching fda web site reveals information opinion scientific committee whether consensus decision concerns addictive potential drug pharmacology vyvanse interesting prodrug lisdexamfetamine conjugate lysine amphetamine absorbed circulation hydrolyzed lysine amphetamine always debate whether prodrug approach confers decreased likelihood compound abused used addictive manner addiction psychiatrists tell fda approved package insert confirms fact significant abuse potential schedule ii drug according dea lesson first amphetamine epidemic drugs prescribed point high demand production drug widespread health consequences noted overprescribing stimulants questionable indications weight loss nasal congestion depression anxiety psychosomatic complaints peak epidemic total number mg amphetamine doses million exceeded combination amphetamine methylphenidate psychiatry resident i still seeing obese people lost pound using high doses amphetamines weight loss indication subsequently banned order establish limits overprescription compounds words taking drug addiction rather using therapeutic effect clear prescription controlled substances diagnoses based subjective findings recipe epidemics addictive drugs terms total prescriptions escalating use diversion stimulant medications additional allure possible performance enhancing drugs widely diverted purpose context would seem fda would need come clear rationale using schedule ii drug treat may time limited disorder disorder responds non medical therapies complex nature medications addictive potential needs recognized prescription compounds takes rote knowledge minimum needs strict pharmacosurveillance drug prescribed flags need place trends indicating prescriptions starting exceed known prevalence disorder dose ranges higher recommended combined short acting stimulants common problems seen overprescription controlled substances passive post marketing surveillance longer considered viable option stopping overprescription controlled substances waiting intervention law enforcement problems already begun approach era data mining commonplace fda lot get drugs marketplace wait see happens george dawson md dfapa mcelroy sl hudson ji mitchell je wilfley ferreira cornwell mc gao wang whitaker jonas gasior efficacy safety lisdexamfetamine treatment adults moderate severe binge eating disorder randomized clinical trial jama psychiatry jan doi jamapsychiatry epub ahead print pubmed pmid nutt david leslie king william saulsbury colin blakemore development rational scale assess harm drugs potential misuse lancet pmid doi supplementary following graph wikimedia commons public domain derivative work reference complete description available link i could find author cite supplementary almost cue i noticed first banner ads binge eating disorder today advertised real medical disorder brief informational film spokesperson talks experience disorder refers interested viewer company web site bingeeatingdisorder carefully coaches people talk doctor pharmaceutical company manufacturer listed bottom page graphic pizza slice drawing brain varies different views i know exactly means suggests psychological therapies mention vyvanse let face people read pill eating problem amphetamine many people asking psychological therapies